Thrive Wealth Management LLC Invests $787,000 in Boston Scientific Corporation $BSX

Key Points

• Thrive Wealth Management LLC purchased a new stake of 7,324 shares in Boston Scientific Corporation, valued at approximately $787,000.
• Boston Scientific reported a 22.8% year-over-year increase in quarterly revenue, with earnings per share (EPS) of $0.75, surpassing analyst estimates.
• Research analysts have issued positive ratings and increased price targets for Boston Scientific, with the consensus rating currently at "Buy" and an average target price of $118.04.

Thrive Wealth Management LLC acquired a new position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,324 shares of the medical equipment provider's stock, valued at approximately $787,000.

Several other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in Boston Scientific by 1.3% during the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock worth $13,577,311,000 after buying an additional 1,697,945 shares during the last quarter. Invesco Ltd. boosted its stake in Boston Scientific by 5.3% in the first quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider's stock valued at $1,677,124,000 after acquiring an additional 834,274 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in Boston Scientific by 10.8% in the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider's stock worth $1,426,779,000 after purchasing an additional 1,383,524 shares during the period. Amundi raised its holdings in Boston Scientific by 2.6% in the first quarter. Amundi now owns 12,308,715 shares of the medical equipment provider's stock worth $1,212,408,000 after purchasing an additional 311,034 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Boston Scientific by 4.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 11,299,942 shares of the medical equipment provider's stock worth $1,139,938,000 after purchasing an additional 460,580 shares during the period. 89.07% of the stock is owned by institutional investors.

Boston Scientific Stock Performance

Shares of BSX stock traded down $0.39 during midday trading on Friday, hitting $97.84. 16,833,754 shares of the company were exchanged, compared to its average volume of 8,034,038. The firm has a market capitalization of $144.97 billion, a P/E ratio of 58.24, a PEG ratio of 2.36 and a beta of 0.65. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The firm's 50 day moving average price is $104.40 and its two-hundred day moving average price is $102.11. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The business had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. Boston Scientific's revenue was up 22.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Buying and Selling at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company's stock, valued at approximately $18,659,923.46. This represents a 21.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the company's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the sale, the director directly owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 174,214 shares of company stock worth $18,397,457. 0.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts recently commented on BSX shares. Needham & Company LLC restated a "buy" rating and set a $121.00 price objective on shares of Boston Scientific in a report on Friday. UBS Group lifted their price target on shares of Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a research note on Thursday, July 24th. Leerink Partners started coverage on shares of Boston Scientific in a research note on Monday, June 16th. They issued an "outperform" rating and a $118.00 price target on the stock. Robert W. Baird lifted their price target on shares of Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a research note on Thursday, July 24th. Finally, Jefferies Financial Group reiterated a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Boston Scientific has an average rating of "Buy" and an average target price of $118.04.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.